Investor Relations Financials & Filings Financial Fundamentals

NASDAQIMMY

Select the financial statements you wish to view below.  The reports below may be viewed on either an annual or quarterly basis.

All financial information contained in this page was current and accurate only as of its respective date, may not have been audited by Imprimis’s independent registered public accounting firm, and represents only a portion of Imprimis’s complete financial statements and related notes, which are contained in the annual and quarterly reports filed with the Securities and Exchange Commission (see the “Annual and Quarterly Reports” tab).  The abbreviated financial information contained on this page should be read in conjunction with Imprimis’s complete financial statements and their related notes, and you are urged to carefully review and consider the various related disclosures made by in the reports filed with the SEC, which discuss the company’s financial results and business in greater detail.
NASDAQIMMY
All numbers in thousands USD
Period Ending
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Total Revenue
9,716
1,660
10
100
Cost of Revenue
5,206
1,093
0
0
Gross Profit
4,510
567
10
100
Operating Expenses
Research Development
332
237
1,616
1,299
Selling General and Administrative
19,000
10,477
6,081
2,980
Non Recurring
--
--
--
--
Others
0
0
0
0
Total Operating Expenses
19,332
10,714
7,697
4,279
Operating Income or Loss
(14,822)
(10,147)
(7,687)
(4,179)
Income from Continuing Operations
Total Other Income/Expenses Net
31
0
0
(1,195)
Earnings Before Interest And Taxes
(14,822)
(10,147)
(7,643)
(5,359)
Interest Expense
--
4
0
25
Income Before Tax
(15,899)
(10,118)
(7,643)
(5,384)
Income Tax Expense
--
--
--
--
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(15,899)
(10,118)
(7,643)
(5,384)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(15,899)
(10,118)
(7,643)
(5,384)
Preferred Stock And Other Adjustments
--
--
0
200
Net Income Applicable To Common Shares
(15,899)
(10,118)
(7,643)
(5,584)
Stay Connected

Imprimis Pharmaceuticals, Inc.
Investor Relations
12264 El Camino Real, Suite 350
San Diego, CA 92130
T: 858.704.4040 | F: 858.345.1745

Contact Us Today

 

Stay Informed

Interested in receiving investor news and updates?

Click Here


Download Imprimis’ IR App for smart phones and tablets for the latest news, reports, presentations and more.


print email